Press releases
- NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
- NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
- NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
- NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
- NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
- NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
- NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
- NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
More ▼
Key statistics
On Thursday, NovaBay Pharmaceuticals Inc (B9P0:FRA) closed at 2.80, 35.59% above the 52 week low of 2.07 set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 2.80 |
Low | 2.80 |
Bid | -- |
Offer | -- |
Previous close | 2.80 |
Average volume | -- |
---|---|
Shares outstanding | 1.35m |
Free float | 1.35m |
P/E (TTM) | -- |
Market cap | 2.90m USD |
EPS (TTM) | -108.80 USD |
Data delayed at least 15 minutes, as of May 30 2024 14:29 BST.
More ▼